WOBURN, Mass.--(BUSINESSWIRE)-- Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX.AX - News), a leading manufacturer of targeted, innovative liver cancer therapies, announced today that dose sales of SIR-Spheres® microspheres in the U.S. grew 29 percent for the second quarter of fiscal year 2013 over the same period last year. Globally the company reported dose sales grew 25 percent year-on-year for the second fiscal quarter of 2013 ending Dec. 31, 2012.
“The sales of SIR-Spheres microspheres in the U.S. continue to grow at a rapid pace due to the investment and execution of the U.S. team. Despite this phenomenal growth, we know there are many more patients who may be able to benefit from this treatment option. Of the nearly 150,000 Americans diagnosed with colorectal cancer every year, at least 60 percent will see their cancer spread to the liver, and many will die of this disease1,” said Mike Mangano, President of Sirtex Medical. “We continue to support the Interventional Radiology community by training new physicians and establishing new treatment sites. At the same time we are focused on educating the Oncology community as to the benefits of our technology, resulting in more patients being referred for our treatment. We were also able to treat our first patients in Argentina in Q2, and will open up additional sites in 2013.”
Dose sales increased in Asia Pacific 37 percent, while 11 percent growth was recorded in Europe, Middle East, and Africa (EMEA).
Sirtex Chief Executive Officer Gilman Wong said, “I am pleased with this result. All four quarters during the 2012 calendar year were very strong and have set a very high benchmark for the 2013 quarters. However, I am confident that our growth performance of the last five years will be maintained.”
For more information, explore the company’s suite of digital platforms including the new global website, Facebook Fan Page community and SlideShare account offering educational materials. Additionally, the new Sirtex SIR-Spheres microspheres Hub iPad app – designed to help physicians share information about the treatment option with patients – is available for download from the Apple iTunes store.
About Selective Internal Radiation Therapy using SIR-Spheres microspheres
Selective Internal Radiation Therapy (SIRT), also known as radioembolization, is a proven technology for inoperable liver cancer that delivers doses of radiation directly to the site of tumors. In a minimally invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.
Clinical studies have confirmed that patients with metastatic colorectal cancer treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone.
SIR-Spheres microspheres are approved for use in Australia, the United States of America (FDA PMA approval), the European Union (CE Mark), and Argentina (ANMAT). Additionally, SIR-Spheres microspheres are supplied in countries such as Hong Kong, Malaysia, Singapore, Thailand, Taiwan, India, Israel, and Turkey. Available at more than 500 treatment centers, over 25,000 doses of SIR-Spheres microspheres have been supplied worldwide.
For more information, visit www.sirtex.com.
SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.
1 SH, Murray T, Bolden S, et al. Cancer Statistics, 1999. CA Cancer J Clin 1999;49: 8 – 31, 31.